Cargando…

Photoreceptor disruption in central serous chorioretinopathy treated by half-dose photodynamic therapy

BACKGROUND: To evaluate photoreceptor disruption in patients with central serous chorioretinopathy (CSC) treated by half-dose photodynamic therapy (PDT). METHODS: A total of 29 patients with symptomatic CSC were recruited and underwent half-dose verteporfin PDT covering the leakage sites as observed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ratanasukon, Mansing, Thongthong, Koblarp, Bhurayanontachai, Patama, Jirarattanasopa, Pichai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3548438/ https://www.ncbi.nlm.nih.gov/pubmed/23345962 http://dx.doi.org/10.2147/OPTH.S39584

Ejemplares similares

High-dose antioxidants for central serous chorioretinopathy; The randomized placebo-controlled study
por: Ratanasukon, Mansing, et al.
Publicado: (2012)

One-year results of half-dose versus one-third-dose photodynamic therapy in chronic or recurrent central serous chorioretinopathy
por: Pichai, Jirarattanasopa, et al.
Publicado: (2021)

Electrophysiologic changes after intravitreal ranibizumab injection for the treatment of choroidal neovascular membrane (CNVM)
por: Bhurayanontachai, Patama, et al.
Publicado: (2011)

Polypoidal choroidal vasculopathy (PCV): the 4-year review of the real-life treatment experiences
por: Ratanasukon, Mansing, et al.
Publicado: (2018)

The Impact of Vision Impairment (IVI) Questionnaire; Validation of the Thai-Version and the Implementation on Vision-Related Quality of Life in Thai Rural Community
por: Ratanasukon, Mansing, et al.
Publicado: (2016)

Surgical outcomes and prognostic factors following vitrectomy in acquired immune deficiency syndrome patients with cytomegalovirus retinitis-related retinal detachment
por: Sittivarakul, Wantanee, et al.
Publicado: (2020)

Results of intravitreal dexamethasone implant (Ozurdex(®)) for retinal vascular diseases with macular edema: An observational study of real-life situations
por: Jirarattanasopa, Pichai, et al.
Publicado: (2022)

Visual outcomes of early and late vitrectomy for breakthrough vitreous hemorrhage associated with exudative age-related macular degeneration and polypoidal choroidal vasculopathy
por: Jirarattanasopa, Pichai, et al.
Publicado: (2023)

Pattern of Contrast Sensitivity Changes in Acute Central Serous Chorioretinopathy
por: Lourthai, Preeyachan, et al.
Publicado: (2017)

Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
por: Naseripour, Masood, et al.
Publicado: (2016)

No-Dose Photodynamic Therapy Against Half-Dose Photodynamic Therapy for Treatment of Central Serous Chorioretinopathy
por: Servillo, Andrea, et al.
Publicado: (2023)

Microperimetric evaluation of chronic central serous chorioretinopathy after half-dose photodynamic therapy
por: Fujita, Kyoko, et al.
Publicado: (2012)

Macular sensitivity after half-dose verteporfin photodynamic therapy in central serous chorioretinopathy
por: Sanguansak, Thuss, et al.
Publicado: (2015)

Choroidal Structure after Half-Dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy
por: Alovisi, Camilla, et al.
Publicado: (2020)

Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy
por: Atik, Alp, et al.
Publicado: (2017)

Outcome of half-dose photodynamic therapy in chronic central serous chorioretinopathy with fovea-involving atrophy
por: van Rijssen, Thomas J., et al.
Publicado: (2020)

Choroidal hemodynamics in central serous chorioretinopathy after half-dose photodynamic therapy and the effects of smoking
por: Horiguchi, Etsuyo, et al.
Publicado: (2022)

The normal choroidal thickness in southern Thailand
por: Jirarattanasopa, Pichai, et al.
Publicado: (2014)

Half-dose verteporfin photodynamic therapy for bullous variant of central serous chorioretinopathy: a case report
por: Ng, Winnie WK, et al.
Publicado: (2011)

Changes in Choroidal Structures in Eyes with Chronic Central Serous Chorioretinopathy after Half-Dose Photodynamic Therapy
por: Kinoshita, Takamasa, et al.
Publicado: (2016)

Short-Term Choriocapillaris Changes in Patients with Central Serous Chorioretinopathy after Half-Dose Photodynamic Therapy
por: Nassisi, Marco, et al.
Publicado: (2017)

Subthreshold micropulse laser photocoagulation versus half-dose photodynamic therapy for acute central serous chorioretinopathy
por: Zeng, Miao, et al.
Publicado: (2022)

INCREASING EVIDENCE FOR THE SAFETY OF FOVEA-INVOLVING HALF-DOSE PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY
por: Feenstra, Helena M. A., et al.
Publicado: (2023)

Photodynamic Therapy and Central Serous Chorioretinopathy
por: Siaudvytyte, Lina, et al.
Publicado: (2012)

Half-fluence photodynamic therapy to treat chronic central serous chorioretinopathy: A case series
por: Al-Hinai, Ahmed S., et al.
Publicado: (2011)

Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy
por: Alkin, Zeynep, et al.
Publicado: (2014)

Choroidal neovascularization secondary to half-dose photodynamic therapy for chronic central serous chorioretinopathy: A case report
por: Zhang, Zhengwei, et al.
Publicado: (2021)

Choroidal vascularity changes in idiopathic central serous chorioretinopathy after half-fluence photodynamic therapy
por: Ma, Dae Joong, et al.
Publicado: (2018)

Long-Term Effect of Half-Fluence Photodynamic Therapy on Fundus Autofluorescence in Acute Central Serous Chorioretinopathy
por: Stattin, Martin, et al.
Publicado: (2020)

Half-fluence Photodynamic Therapy for Central Serous Chorioretinopathy in a Patient Receiving Corticosteroids for Behçet’s Uveitis
por: Özdemir, Hüseyin Baran, et al.
Publicado: (2022)

Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy
por: Fujita, Kyoko, et al.
Publicado: (2020)

Decrease in choroidal blood flow after half and one-third dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy
por: Kumashiro, Shun, et al.
Publicado: (2021)

The relationship between foveal outer nuclear layer thickness in the active and resolved phases of central serous chorioretinopathy treated with half-dose photodynamic therapy
por: Yu, Jia, et al.
Publicado: (2019)

3-year follow-up of half-dose verteporfin photodynamic therapy for central serous chorioretinopathy with OCT-angiography detected choroidal neovascularization
por: Hu, Yu-Chen, et al.
Publicado: (2021)

Long-Term Effects of Half-Time Photodynamic Therapy on Retinal Sensitivity in Eyes with Chronic Central Serous Chorioretinopathy
por: Iwase, Takehito, et al.
Publicado: (2020)

Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization
por: Kamimura, Aya, et al.
Publicado: (2023)

Structural and Functional Outcomes in Chronic Central Serous Chorioretinopathy Treated with Photodynamic Therapy
por: Cidad, Pino, et al.
Publicado: (2015)

Real world outcomes of photodynamic therapy for chronic central serous chorioretinopathy
por: Khandhadia, Samir, et al.
Publicado: (2022)

Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: A 3-year follow-up study
por: Haga, Fuminori, et al.
Publicado: (2017)

Assessment of choriocapillary blood flow changes in response to half-dose photodynamic therapy in chronic central serous chorioretinopathy using optical coherence tomography angiography
por: Liu, Juejun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_eq26llsj4ji01r46ncekurt6uh